Conducting Psychedelic Retreats Abroad: Protecting Yourself and Participants
Facilitating International Psychedelic Retreats
“Sincere Religious Belief” is an Evolving Standard for Psychedelic Churches
A potential expansion of the religious use of psychedelic substances
Ninth Circuit Issues Disappointing Ruling on Terminally Ill Patients and Psilocybin
Ninth Circuit sides with DEA on doctors petition to seek waiver under Right to Try laws
Oregon Psilocybin: State of the State (2024)
The end of 2024 marks two years in the books for the Oregon Psilocybin Services (OPS) program. It has been a long road: in my year-end 2023 post, I explained that the program was incubated on a protracted, two-year runway prior to launch. This mean we are four years along, with two years of live
Updates on MDMA, Ketamine, and the Future of Psychedelic Therapies
Over the last few weeks, the federal government has taken a number of actions that signal a dark future for psychedelic therapies. Today we’ll take a quick look at what’s happened, and what may happen in the future. FDA gives thumbs down to MDMA Earlier in August, the FDA opted not to approve Lykos Therapeutics’
Oregon Psilocybin: Preparing for the End of Local Ownership Rules
Oregon’s rule limiting the non-resident ownership of licensed psilocybin businesses sunsets on December 31, 2024. That’s a little over six months away. Six months is not that long, especially in the context of getting to know an industry or a business, and putting a thoughtful deal together– one that will generate reasonable returns for an
Psychedelics and the Military: An Unlikely Alliance
Despite decades of stigma and legal barriers, recent years have brought a profound shift in attitudes towards psychedelics. Driven by scientific inquiry and a growing recognition of their potential therapeutic benefits, the benefits of psychedelics are being explored. In this blog post, we explore the impact of an unexpected catalyst driving progress in psychedelics research–
Arizona’s Psilocybin Legislation
Psilocybin’s therapeutic renaissance Once relegated to the realm of recreational drug use, psilocybin is now at the forefront of a discussion on the potential therapeutic benefits of psychedelics. Arizona is the latest state to take up the discourse: its proposed Senate Bill 1570 (SB 1570) would establish licensed psychedelic-assisted therapy centers, and advance scientific research
Oregon Ketamine Clinics: New Potential Restrictions on Corporate Practice of Medicine
Should private equity be involved in health care? If so, in what types of settings? And to what extent? These are baseline considerations around a broad concept referred to as “corporate practice of medicine” (“CPOM”) that state legislatures, agencies, medical licensing boards, courts and attorneys general and grappled with for over a century. The Oregon
California Bill Proposes Psychedelic Assisted Therapy Workgroup
California recently failed at least twice in passing sweeping statewide psychedelic decriminalization bills: a) SB-58, which Governor Gavin Newsom vetoed last year, and b) SB-519, which didn’t garner enough support in the assembly the year before. It’s now trying something much more modest – convening a workgroup to study psychedelic assisted therapy. The bill at